Tafolecimab 450 mg Q4W reduced Lp(a) levels by 33-41%, with 36.5% achieving >50% reduction versus 6.7% on placebo at 12 weeks in hypercholesterolaemic patients.
Does tafolecimab reduce Lp(a) levels in hypercholesterolaemic patients?
Tafolecimab 450 mg Q4W significantly reduces Lp(a) levels in hypercholesterolaemic patients, with potent reductions observed across varying baseline Lp(a) categories.
Absolute Event Rate: 0% vs 0%
Abstract Background High levels of lipoprotein(a) Lp(a) are recognised as an independent risk factor for arteriosclerotic cardiovascular disease, particularly with Lp(a) levels 50 mg/dL. The CREDIT phase 3 trials have demonstrated that tafolecimab effectively reduces levels of low-density lipoprotein cholesterol (LDL-C) and Lp(a) in Chinese patients with hypercholesterolaemia. However, its efficacy on lowering Lp(a) among patients with very high baseline Lp(a) levels is not well defined. Purpose This study evaluated the efficacy of tafolecimab on Lp(a) in patients with hypercholesterolaemia by pooling data from three phase 3 trials. Methods This pooled analysis included 734 hypercholesterolaemic participants from three multicentre, double-blind, phase 3 randomised controlled trials, with 494 participants receiving tafolecimab 450 mg every four weeks (Q4W) and 240 participants receiving placebo Q4W. The primary efficacy endpoint was the percentage reduction in Lp(a) levels from baseline at 12 weeks. According to the 2022 European Atherosclerotic Society Lp(a) consensus statement, the baseline Lp(a) levels were categorised as: 30 mg/dL, ≥30 mg/dL but 50 mg/dL, and ≥50 mg/dL. Results At baseline, the mean Lp(a) levels were comparable between the tafolecimab and placebo groups (22.9 mg/dL vs. 23.4 mg/dL, P 0.05). By week 12, tafolecimab significantly reduced Lp(a) levels compared to placebo (-10 mg/dL vs. -1 mg/dL, P 0.0001). A significantly greater proportion of participants treated with tafolecimab achieved a 50% reduction in Lp(a) levels than the placebo group (36.5% vs 6.7%, P 0.0001). Additionally, for participants with baseline Lp(a) levels 30 mg/dL and Lp(a) ≥50 mg/dL, tafolecimab induced significant reductions in Lp(a) compared with placebo at week 12 Lp(a) 30 mg/dL: mean difference=-33.82%, 95% CI: -39.77%, -27.87%; Lp(a) ≥50 mg/dL: mean difference=-33.66%, 95% CI: -43.55%, -23.76%. Those with baseline Lp(a) levels between 30 and 50 mg/dL experienced a more potent reduction of Lp(a) levels (mean difference=-41.38%, 95% CI: -53.91%, -28.84%). Conclusions Tafolecimab 450 mg Q4W offers greater reductions in Lp(a) levels in hypercholesterolaemic patients with higher initial Lp(a) levels, which provides a novel therapeutic option for improving Lp(a) and preventing cardiovascular risks for this patient population.
Qi et al. (Sat,) reported a other. Tafolecimab 450 mg Q4W reduced Lp(a) levels by 33-41%, with 36.5% achieving >50% reduction versus 6.7% on placebo at 12 weeks in hypercholesterolaemic patients.